| Business Summary | | Mylan
Laboratories
Inc.
is
engaged
in
developing,
licensing,
manufacturing,
marketing
and
distributing
generic
and
brand
pharmaceutical
products.
The
Company
conducts
business
through
its
generic
(Generic
Segment)
and
branded
(Brand
Segment)
pharmaceutical
operating
segments.
Mylan
sells
its
products
primarily
to
proprietary
and
ethical
pharmaceutical
wholesalers
and
distributors,
drug
store
chains,
drug
manufacturers,
institutions
and
governmental
agencies
within
the
United
States.
The
Company's
Generic
Segment
consists
of
two
principal
business
units,
Mylan
Pharmaceuticals
Inc.
and
UDL
Laboratories
Inc.
Mylan's
Brand
Segment
operates
principally
through
its
wholly
owned
subsidiary,
Bertek
Pharmaceuticals
Inc. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Mylan
Laboratories
Inc.
is
engaged
in
the
development,
licensing,
manufacturing,
and
marketing
of
generic
and
proprietary
finished
pharmaceutical
and
wound
care
products.
For
the
three
months
ended
6/30/01,
revenues
rose
42%
to
$237.9
million.
Net
income
totalled
$50.6
million
vs.
a
loss
of
$76.1
million.
Revenues
reflect
increased
generic
segment
sales
and
the
introduction
of
Buspirone.
Net
income
also
reflects
the
absence
of
a
$147
million
litigation
charge. | More
from
Market Guide: Significant
Developments |
| | | | FY2001 Pay | |
| Milan Puskar, 66 Chairman,
CEO | $1.6M | C. Todd, 67 Pres,
COO, Director | -- | Gary Sphar, 47 Interim
CFO, VP-Fin. | -- | Dana Barnett, 60 Exec.
VP | -- | James Mauzey, 52 Exec.
VP; and Pres and CEO, Bertek Pharmaceuticals Inc. | -- | Dollar
amounts are as of 31-Mar-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|